Canada Markets closed

Brooklyn ImmunoTherapeutics, Inc. (BTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.6700-0.0800 (-2.91%)
At close: 04:00PM EST
2.6700 0.00 (0.00%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close2.7500
Open2.7000
Bid2.6000 x 800
Ask2.6700 x 1000
Day's Range2.5800 - 2.7950
52 Week Range2.5800 - 80.6700
Volume541,281
Avg. Volume539,996
Market Cap138.957M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.4470
Earnings DateMar. 09, 2022 - Mar. 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
  • GlobeNewswire

    Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors

    NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Company’s Board of Directors. Erin S. Enright has served on multiple Boards of Directors, including within the medical and life sciences arenas, such

  • GlobeNewswire

    Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio

    NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces that 18 new patents were issued and 17 new patent applications were filed in 2021. The intellectual property is owned by Factor Bioscience (“Factor”) and exclusively licensed to Brooklyn for

  • GlobeNewswire

    Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index

    NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces that Brooklyn has been added to the ICE Biotechnology Index (NYSE:ICEBIO) following the December 20, 2021 reconstitution. “The continued recognition of Brooklyn among key biotechnology indices